Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Trina Mukherjee headshot

Digital Diabetes Management Gains Momentum: 3 Stocks in Focus

by Trina Mukherjee

With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.

The Zacks Analyst Blog Highlights: Abbott, Philip Morris, Lowe's, Equinix and Kinder Morgan

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott, Philip Morris, Lowe's, Equinix and Kinder Morgan

Mark Vickery headshot

Top Analyst Reports for Abbott, Philip Morris & Lowe's

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), Philip Morris International (PM) and Lowe's Companies (LOW).

Abbott (ABT) Up 2.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medical Products' Nov 7 Earnings Roster: ABC, CAH & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

3 Medical Product Stocks Likely to Beat This Earnings Season

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Urmimala Biswas headshot

Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More

by Urmimala Biswas

Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.

Medical Products' Oct 30 Earnings Roster: MCK, MASI & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.

Medical Products' Oct 24 Earnings Roster: BAX, CERN & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abbott's (ABT) performance.

Medical Products' Earnings Roster for Oct 23: TMO, BSX & More

by Zacks Equity Research

Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

Urmimala Biswas headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

by Urmimala Biswas

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Abbott (ABT) Meets Q3 Earnings Estimates, Lowers EPS Guidance

by Zacks Equity Research

We are optimistic about Abbott's (ABT) strong and consistent EPD and Medical Devices performance organically.

Abbott (ABT) Meets Q3 Earnings Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 0.00% and -0.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Can Structural Heart Strength Aid Abbott (ABT) Q3 Earnings?

by Zacks Equity Research

Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.

Abbott Forms Alliance With Omada Health for Diabetes Care

by Zacks Equity Research

Abbott (ABT) collaborates with Omada Health to revolutionize diabetes care by expanding technological access.

Can Balanced Segmental Growth Aid Abbott (ABT) Q3 Earnings?

by Zacks Equity Research

Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $79.62, moving -0.65% from the previous trading session.

Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axonics (AXNX) Upbeat on Results of Its ARTISAN-SNM Study

by Zacks Equity Research

Axonics (AXNX) expects to improve performance on the positive outcome of the study.

Abbott (ABT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $81.97, moving +1.11% from the previous trading session.

Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test

by Zacks Equity Research

The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.

Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT

by Zacks Equity Research

Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.

Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System

by Zacks Equity Research

Abbott (ABT) is upbeat about the latest clearance in its neuromodulation product portfolio.